TUCATINIB

Information current as at: 1 June 2026

PBAC meeting date: May 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • TUKYSA®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Pfizer Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Breast cancer
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Review of positive PBAC recommendations not accepted by applicants (–)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
May 2026 PBAC meeting
Opportunity for consumer comment:
Open 23/12/2020 and close 11/02/2021 (see PBS Website)
PBAC meeting:
Held on 08/05/2026
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a1253
Page last updated
31 May 2026
Return to the Medicine Status Listing
v.9.19